Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation-Reference-Cited by-同舟云学术

Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation

Published:2024-06-04 Issue: Volume: Page:1-8
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Falcone Marco¹,Tiseo Giusy¹,Marchetti Gabriele¹,Kalo Jona¹,Galfo Valentina¹,Occhineri Sara¹,Almerigogna Francesco¹,Matucci Tommaso¹,Riccardi Niccolò¹,Suardi Lorenzo Roberto¹,Rina Ines²,Sijoni Ledja²,Caparello Maria Costanza²,Cassano Cassano Raffaella²,Del Giudice Maria Livia²,Franciosa Marinunzia²,Facella Flaminia²,Tancredi Gaspare²,Fazzi Rita²,Galimberti Sara²

Affiliation:

1. Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy

2. Hematology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2361099

Reference34 articles.

1. CDC. People with certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#:∼:text=Older%20adults%20are%20at%20highest people%20ages%2018%2D29%20years.

2. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: results from the EPICOVIDEHA registry;Musto P;Hematol Oncol,2024

3. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey;El-Ashwah S;Leuk Lymphoma,2024

4. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings;Rossi G;Int J Infect Dis,2023

5. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study;Viruses;2024-08-22